Trump unveils new agreement with a pharmaceutical company, fulfilling his campaign pledge to cover all IVF expenses.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2025
0mins
Source: MarketWatch
Trump's Announcement: President Donald Trump announced a deal with EMD Serono to reduce out-of-pocket costs for in vitro fertilization (IVF) treatments, fulfilling a campaign promise made over a year ago.
Discounts on Fertility Drugs: EMD Serono, the largest fertility drug manufacturer globally, will provide significant discounts on all fertility drugs sold in the U.S., including the widely used IVF drug Gonal-f.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.440
Low
24.00
Averages
28.56
High
35.00
Current: 26.440
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Struggles to Compete in GLP-1 Weight Loss Market
- GLP-1 Drug Competition: Pfizer lags behind Eli Lilly and Novo Nordisk in the GLP-1 weight-loss market due to the abandonment of its internal candidate, resulting in lost market share and impacting future revenue growth.
- Patent Cliffs Approaching: Pfizer's oncology drug Ibrance is expected to face generic competition in 2027, with cardiovascular drugs Eliquis and Vyndaqel losing patent protection in 2028, potentially leading to significant revenue declines.
- High Dividend Payout Ratio: Pfizer's dividend payout ratio hovers around 100%, raising concerns about sustainability in light of setbacks in GLP-1 drug development and approaching patent cliffs, which could affect future dividend stability.
- Investor Confidence Eroded: While Pfizer remains a significant pharmaceutical player, the challenges it faces have led to investor unease regarding its future performance, especially with key drug revenues potentially declining in 2026.
Continue Reading
Positive Trading Outlook for Simon Property Group
- Price Upside Potential: Simon Property Group's shares have risen 3% this year and are nearing their 52-week high, with market analysts predicting a rally into the low $200s following Monday's earnings report, indicating strong market confidence.
- Long-Term Growth Outlook: According to the chief market strategist at Freedom Capital Markets, Simon's long-term trend shows significant upside potential, with expectations that the stock could reach between $220 and $250 over the next six to twelve months, reflecting investor optimism about its future performance.
- Pfizer Stock Focus: Jay Woods is also watching Pfizer, believing its downtrend has ended; if it can break above $27 and hold, the stock could rise to $32, highlighting its appeal in the current market environment.
- Market Dynamics Analysis: Woods discusses key levels to watch on the S&P 500 this week, along with trading levels for Biogen, Palantir, Amazon, and Alphabet, indicating that market participants should closely monitor these companies' performances to seize investment opportunities.
Continue Reading